

A Work Project, presented as part of the requirements for the Award of a Master's degree in
Finance from the Nova School of Business and Economics.

PREVENTICO - TACKLING CHRONIC KIDNEY DISEASE USING WEARABLE
BIOSENSORS

KAREMA HASCHEMI

Work project carried out under the supervision of:

NUNO ARANTES-OLIVEIRA

20/05/2022

Abstract

The Building Companies Based on Science Field Lab (FL) challenged students to explore a scientific breakthrough and build a business plan with the ultimate goal of creating a new venture. Throughout the FL, the group of students explored a real problem and its effects on society. From then, they identified a new and unique solution to tackle the initial problem, by pursuing market research, sizing, and a deep analysis of all stakeholders involved. In later stages, students also developed a financial analysis where fundraising needs were identified, as well as potential strategic partnerships, critical skills, valuation, and possible exit scenarios. This final document encompasses all the elements necessary to pitch to potential partners and investors.

Keywords: Venture Capital, Entrepreneurship, Innovation, Science, Leadership, Market Research, R&D, Start-up, Entrepreneurial Finance, MedTech, Kidney Disease, Wearables, Biosensors, Commercial, Business Strategy, Operations.

This work used infrastructure and resources funded by Fundação para a Ciência e a Tecnologia (UID/ECO/00124/2013, UID/ECO/00124/2019 and Social Sciences DataLab, Project 22209), POR Lisboa (LISBOA-01-0145-FEDER-007722 and Social Sciences DataLab, Project 22209) and POR Norte (Social Sciences DataLab, Project 22209).

EXECUTIVE SUMMARY

850 million people are affected by chronic kidney disease (McCullough 2019), and its treatment in the late stages imposes massive financial burdens on the patient and the country's economy. But the progression of chronic kidney disease can be slowed or completely stopped if diagnosed and treated early. (National Kidney Foundation 2015)

Our soon-to-be-founded company, Preventico, will introduce the first commercially viable wearable device, the SIKMA, to the U.S. market. The device will allow medical professionals to actively monitor and manage patients at risk of getting a chronic kidney disease. On our way to market, we will:

- Raise an initial seed funding round to establish our company in the U.S. and hire an internal software development team to start work on the accompanying software.
- Engage an experienced agency providing electronic manufacturing services to handle the development of the hardware product until it is ready to market.
- Secure existing knowledge by retaining the current scientific advisory board and pursuing an active intellectual property strategy for existing and future inventions.

The successful setup of our company and teams will allow us to be the first company to enter the market with a commercial, clinically validated product that allows for the monitoring of chronic kidney disease. Initial responses show that this would create value for all levels of users: patients, doctors, and health insurance providers. A successful market entry will allow the company to continue research and development efforts in biomarkers to treat more chronic diseases. It will demonstrate the company's value to enable us, the founders, and the initial investors to exit the company through an acquisition.

TABLE OF CONTENTS

EXECUTIVE SUMMARY 2

INTRODUCTION 7

THE PROBLEM: CHRONIC KIDNEY DISEASE 8

CAUSES..... 8

DIAGNOSIS..... 8

TREATMENT & PREVENTION 10

WHY IS THIS A PROBLEM? 11

 BURDEN TO HEALTHCARE 12

 WHAT IS THE SOLUTION FOR THIS? 13

OUR PRODUCT 15

MEDICAL PRODUCT APPROVAL 17

CHALLENGES IN PRODUCT DEVELOPMENT 19

ROADMAP FOR PRODUCT DEVELOPMENT 20

OUR COMPANY..... 21

WEARABLE BIOSENSORS MARKET 23

TRENDS 23

EPIDERMAL WEARABLE BIOSENSORS..... 25

WEARABLE BIOSENSORS AND KIDNEY DISEASE..... 26

OUR MARKET 27

Group Contribution

THE U.S. KIDNEY DISEASE MARKET 27

WHY THE U.S.? 28

OPPORTUNITIES IN THE U.S. MARKET 30

COMPETITORS **31**

SUBSTITUTES & ALTERNATIVES 32

MARKET POSITION **33**

TARGET SEGMENTS 34

POSITIONING 35

MARKETING PLAN **36**

VALUE PROPOSITION 36

PROMOTIONAL ACTIVITIES 38

PEOPLE 40

CUSTOMER JOURNEY 40

THE BUSINESS **42**

KEY ACTIVITIES 42

VALUE CHAIN 42

KEY RESOURCES 43

INTELLECTUAL PROPERTY STRATEGY 44

KEY PARTNERS 46

DRIVERS OF COST 47

Group Contribution

REVENUE STREAMS 48

MEDICARE AND REIMBURSEMENT 48

PRICING STRATEGY 49

SOURCES OF FUTURE GROWTH..... 50

THE TEAM..... 51

NEEDED SKILLS AND EXPERTISE..... 53

SCIENTIFIC ADVISORY BOARD 54

FINANCIAL SITUATION 55

INVESTMENT CRITERIA FOR MEDTECH STARTUPS..... 56

SOURCES OF FUNDING..... 57

OUR FUNDING STRATEGY 59

RISKS IN SECURING EARLY-STAGE FUNDING 62

CAPITALIZATION TABLE 63

EXIT STRATEGY..... 65

TIMELINE & KEY MILESTONES 67

CONCLUSION 70

REFERENCES 73

APPENDIX..... 84

Appendix I - CKD patients interviews insights 84

Appendix II - Additional potential investors for the current and upcoming rounds 86

Group Contribution

Appendix III: CKD treatment roadmap..... 87

Appendix IV - Memo: Correspondence with Cre8tek 88

Appendix V - Memo: Interview with Andy D...... 89

Appendix VI - Memo: Correspondence with Paulo Zoio 90

Appendix VII - Memo: Correspondence with Tony Orsi..... 91

Appendix VIII: Timeline & key milestones..... 92

Appendix IX: Income statement forecast..... 93

Appendix X: Estimated patent costs 93

Appendix XI: interview overview with different stakeholders..... 94

INTRODUCTION

Today, 10% of the worldwide population is affected by chronic kidney disease, with 2 million people receiving treatment through dialysis or a transplant. A number that might only cover 10% of people that need treatment to live. (National Kidney Foundation 2015) Chronic kidney patients must closely monitor their disease daily to mitigate the consequences and live longer lives. But precise monitoring requires frequent in-person visits to the doctor's office, and in the current climate only happens once a month. Chronic kidney disease is costly for the patient mentally and physically, but it also grows increasingly expensive to treat as the disease progresses. The earlier prevention can be done, the better for the patient and the cheaper the treatment will be.

Our new health tech company Preventico is setting out to solve these problems because we see a future where preventing diseases is the new standard instead of treating them. We believe that you can get preventive treatment right on time by actively monitoring your health status and communicating it with your medical team. That is why we are developing the first commercially available smart device for the U.S. market that combines hardware, advanced algorithms, medical knowledge, and user-friendly software to bring healthcare providers and patients the ability to treat chronic kidney disease earlier and communicate more effectively.

Chronic kidney disease is just the start. In the future, we are aiming to expand our product offering with an extensive library of chronic diseases that can be monitored through newly discovered biomarkers by simply wearing a smartwatch.

OUR PRODUCT

In recent years, wearable biosensors have become a new product category. Their ability to provide continuous real-time data about a person's physiology and the increased accuracy and effectiveness have made these devices reliable and commercially viable. Developments made in recent years have focused on electrochemical and optical biosensors, and major advancements have been made in the non-invasive monitoring of biomarkers such as bacteria, hormones, and metabolites. (Kim, et al. 2019)

Developing a new commercial product is influenced by normative, cognitive, and regulatory institutions. Normative institutions encompass the principle of evidence-based medicine and practical guidelines. Cognitive institutions deal with product and industry standards and users' expectations of the product category. Lastly, the medical industry is heavily influenced by regulatory requirements for medical devices, patent laws, public procurement laws, and reimbursement systems. (Hedefjall and Titkova 2015)

Preventico will introduce our first product in the wearable biosensors category: the SIKMA. SIKMA focuses on monitoring patients suffering from or at risk of getting chronic kidney disease (CKD). The product is more than a wearable device, as it includes hardware, advanced machine learning algorithms, and user-friendly software.

Looking at the hardware, SIKMA is a novel, discrete wearable device that can be worn all day long. The device is a skin-born solution, a group of devices that have gotten increased attention as the other layer of skin, the epidermis, covers our body. The device features an optical mini near-infrared sensor and two small electrodes that allow the device to measure the wearer's hydration status and sample interstitial fluid (ISF) through reverse iontophoresis, from which the infrared sensor can measure the concentration of urea and potassium with.

Group Contribution

ISF is the fluid surrounding the cells that provide nutrients that disseminate directly from the capillary endothelium, which means that correlations can be made between blood and ISF concentrations of different chemical substances such as potassium and urea. To bring ISF to the skin's surface in a non-invasive manner, SIKMA will use reverse iontophoresis that transports molecules through the skin using small amounts of electricity without harming the surface or being in contact with blood. (Kim, et al. 2019) (Xu, Yunsheng and Chen 2021). The device measures urea as this is currently the gold standard for detecting CKD, traditionally measured through blood samples. The kidney will normally remove urea if it is functioning, and higher than average concentrations are, therefore, a clear sign of CKD and can be used for diagnosing. (Mayo Clinic 2021) Potassium is a mineral present in food, which helps keep the heartbeat regular and muscles working right. Healthy kidneys will ensure that your body contains the right amount, but with CKD, the levels can reach dangerous levels that can result in an irregular heartbeat or a heart attack. Therefore, it is vital to know when suffering from a CKD to take proper measures, e.g., adjusting your diet. (National Kidney Foundation 2022)

After the sensor has measured the values, the SIKMA transfers the data to the user's phone for further processing via the Bluetooth protocol. After the data has been transferred, SIKMA's companion app will upload it to Preventico's cloud for processing. Our proprietary machine-learning algorithms use the data to determine the user's health condition to try and predict how a user currently suffering from a CKD's condition might evolve. The algorithms are trained based on data from previously diagnosed patients at various stages and aim to provide insights into the prognosis of a CKD patient.

The resulting values from the algorithms are then returned to the app for the user, and a copy is shared with the user's linked medical team. In the app, the user will see the measured value of urea, potassium, and hydration on a scale of low, regular, and high. The user will also be able

Group Contribution

to see historical values from previous measurements to understand how they have developed over time. The app will also allow the user to securely communicate with the medical team about their numbers through chat messages. On the other end, the medical team will have access to a dashboard, where they can log in and access the data of all the patients who have chosen to share their data with them. This enables them to see how the patient is performing and gives greater insight to help create a better diagnosis and prognosis for the patient and optimize the treatment the patient is receiving. The patient's health status data will also automatically trigger follow-ups, so the medical team can efficiently handle their patients based on severity.

All in all, SIKMA aims to create value for both patients and medical professionals by allowing for more precise data and disease tracking so that the patient can feel secure every day and the medical professional can provide more accurate treatment.

MEDICAL PRODUCT APPROVAL

Medical devices sold in the United States are regulated by the Food and Drug Administration (FDA), where companies need to register the product and gain approval. The FDA regulates the sale of medical devices and monitors the safety of every regulated medical device to ensure safety and effectiveness for its use case. (FDA 2018)

For SIKMA to obtain FDA approval, it will have to go through the following five steps:

- 1. Device Discovery and Concept** – first, we'll have to know which class SIKMA belongs to, from Class I to Class III. This classification is based on risk, meaning the risk the product presents to the user (lowest to highest). Class II and Class III are subject to pre-market reviews, unlike Class I medical devices. Usually, wearable devices to monitor health parameters are classified into Class II, which have special controls, in addition to

Group Contribution

general controls, including labeling requirements, guidance, tracking, plan, performance standards, and post-market observation. (FDA 2018)

2. **Preclinical Research** – Prototype: the second step is to develop a prototype to be used for testing in laboratory environments, reducing its risk enough before it is used in humans, and answering basic questions about safety. (FDA 2018)
3. **Pathway to Approval** – the product is tested on humans to ensure that it is safe and effective. The regulatory controls for devices include, for example:
 - a. **510(k) process:** requires proof that the device is substantially equivalent to a legally marketed device, that is if it has the same expected use and technological characteristics as a legally marketed device. If the FDA determines that the device is not substantially equivalent, we might be asked to submit a premarket approval application.
 - b. **Premarket Approval Application (PMA)** – scientific and regulatory review necessary to determine a device’s safeness and effectiveness, requiring scientific evidence that the possible benefits surpass the potential risks and that it will substantially benefit an extensive portion of the target population.
4. **FDA Review** – FDA review teams examine all submitted data, and if they have enough information on the device’s safety and effectiveness, they can apply to market the device to the public. (FDA 2018)
5. **FDA Post-Market Safety Monitoring** – FDA controls the device’s safety once it is available for public use through manufacturer inspection, developing programs to allow for problem reporting, and keeping active surveillance. (FDA 2018)

For Class II devices, which the SIKMA is expected to fall into due to its similarity to existing products such as the Apple Watch 4 (Su 2018), the average length of time for FDA approval is

Group Contribution

normally six months. However, it may take three to seven years from concept to approval, including the device lifecycle, R&D, and testing.

CHALLENGES IN PRODUCT DEVELOPMENT

In our development of the SIKMA, we will face a set of challenges that has to be overcome to make the product commercially viable:

- 1. Data security.** As Preventico and the SIKMA is reliant on storing and processing medical records for the product to function, we fall under the rules of the Health Insurance Portability and Accountability Act (HIPAA) that protects individually identifiable health information, such as your current health status (U.S. Department of Health & Human Services 2013) (U.S. Department of Health & Human Services 2022). We solve this issue by actively thinking data security into our software while developing it and conducting cybersecurity audits regularly in our company.
- 2. Hardware.** We are facing three main challenges at the hardware level: connectivity, battery life, and portability. The first two challenges are universal across all wearable devices and will be mitigated with BLE (Bluetooth low energy) for communication and spacing between information sent to the wearer's device. This will also positively impact battery life together with the choice of using the phone for further data processing.
- 3. Medical approval.** Lastly, the challenge is getting the device approved by the FDA as a medical device. This is a crucial step to ensure its reliability and that we can introduce the product to the market as a clinical device, significantly increasing our credibility. This process can take between 3-7 years, and as our product category is new to the market, we find that 7 years from initial conception to an approved product is most realistic.

Group Contribution

ROADMAP FOR PRODUCT DEVELOPMENT

To pursue the development of a first device like the one described above, the following roadmap for the hardware device and its accompanying software will be followed by the company within the first two years of operating to create our first fully working prototype:




Figure I: Roadmap for the development of the SIKMA

OUR COMPANY

Preventico is a health-tech startup developing the SIKMA by combining the power of advanced machine learning, modern wearable technology, and user-friendly software to assist the world's medical professionals in providing chronically ill patients with the best possible disease management program adapted to their unique situation and health condition.

Preventico will be founded in 2022 by Karema Haschemi, Madalena Lara, and Sigurd Koldste in Boston, MA, USA, to initially help chronic kidney disease patients to get treated earlier and more efficiently manage their disease, in collaboration with their team of medical professionals. The group met during their studies at Nova School of Business and Economics and decided to take on the challenge of creating a new solution that could successfully move how chronic diseases are treated late to facilitating a more preventative approach, where they can be uncovered early before they seriously impact people's lives. We see our mission as being:

Keeping your health up to date every single day, empowering you and your medical team to act before it is too late.

Preventico has a strong vision for the future, where we aim to move the medical world from treating to preventing disease, empowering medical professionals along the way to act in their best interest:

Imagine a future where looking at your wrist, you do not only know what time it is, but you know how your overall health is.

In the pursuit of this vision, we are sticking to a core set of five fundamental values that encompass all our work:

Group Contribution

- ***Integrity.*** We treat our users and customers with integrity in all interactions and design our products to do the same.
- ***Transparency.*** Our entire company aims to be fully transparent, so you can safely entrust us with your personal life.
- ***Collaboration.*** We collaborate with everybody interested in detecting the fingerprints of more diseases, so we as a team can help more people worldwide.
- ***Curiosity.*** We were born out of curiosity, and we stay curious about everything, so we might learn how to help you better.
- ***Diversity.*** If we are indeed to help everybody, we need to embrace diversity as part of our organization and when developing our company.

COMPETITORS

There are several features that allow Preventico to deliver a superior solution to tackle kidney disease more efficiently than its competitors. Our product, SIKMA, integrates a patient application that allows the user to see the values continuously, alerting both patient and health professional about potential harming values, all done in a non-invasive manner. We also provide an all-in-one solution by gathering the data, treating it with machine learning algorithms, and presenting it to the healthcare team and patient without needing to access data from external sources, unlike the other companies that are reliant on data from 3rd party devices, since they do not have their own device.

Table II shows the direct competitors we have identified in the U.S. market. They can be classified into two groups: 1) focused on assisting healthcare professionals, and 2) on assisting patients through their CKD journey:

- *Monogram Health* and *Strive Health* are more oriented towards the patient experience with CKD, helping clinicians to work with patients during the development and implementation of their disease management plan. With machine learning technology, these companies identify gaps in the cycle of care, predict avoidable acute events and keep track of crucial biomarkers remotely. *Monogram Health* furthermore provides additional services such as hotlines patients can call to ask for advice from a team of specialists.
- *Renalytix* and *pulseData* are more oriented towards medical professionals, being data-based companies that aim to help with the earlier detection and diagnosis of CKD based on proxies and biomarkers collected from a range of different sample types.

Group Contribution

- All four companies mentioned above work to predict the patient journey, following individuals through the whole cycle of care, with the purpose of optimizing their disease management plan.
- Of the listed competitors, *One Drop* is an outlier since it does not tackle CKD directly. However, it monitors parameters of other underlying diseases that can lead to kidney disease. *One Drop* focuses on promoting a healthy lifestyle for the patient by having a balanced diet and doing physical exercise, with an approach more focused on health data tracking and coaching.

Company	Location	Commercially available?	For CKD patients?	Patient app?	Non-invasive?	Score
One Drop	New York, NY	✓	✓	✓	(✓)	3.5
Monogram Health	Nashville, TN	✓	✓	✓	?	3
Strive Health	Denver, CO	✓	✓	?	✗	2
Healthy.io	Boston, MA	✓	✓	(✓)	✓	3.5
Renalytix AI	New York, NY	✓	✓	✗	✗	2
pulseData	New York, NY	✓	✓	✗	✗	2
Preventico	Boston, MA	✓	✓	✓	✓	4

Table II: Comparison of competitors for the SIKMA by Preventico

SUBSTITUTES & ALTERNATIVES

The main substitute products for the SIKMA can be found within several wearables designed for comorbidities and complications that CKD patients commonly suffer from. These include cardiovascular disease, diabetes, and general fitness (Wieringa, et al. 2017). For monitoring these related illnesses, the most common products are: 1) weighing scales to determine the fluid

Group Contribution

weight, 2) blood pressure monitors to assess the risk of heart failure, 3) glucometers as diabetes is a common related disease, 4) pulse oximeters to measure oxygen levels and heart rates, and lastly 4) wearable ECG monitors a growing feature among smartwatches such as the Apple Watch. (DrKumo Inc. 2021)

The substitutes are wide-ranging, and some share closer characteristics with being alternatives, as they become more distant for directly monitoring and optimizing the treatment and conditions of living with CKD. In our analysis of the direct competitors, these devices can be found as used as part of the data input used on their platforms. The common issue is that they are proxies around CKD but do nothing to monitor the condition itself directly.

Our market survey also highlighted a growing number of companies offering a similar solution to that of the SIKMA but targeted at diabetes at different stages of commercial availability. This range of products will be kept under consideration, as they are for now not directly competing with the SIKMA but will grow to become a part of the substitute and alternative products.

MARKET POSITION

We consider there to be two different types of segments for our product: users and buyers.

Within users, we have two unique segments that are using the product in different ways:

1. CKD patients wear the device daily and use it to get information about their health status and communicate this to their medical team.
2. Medical professionals prescribe the device to their patients, so they can more easily track their patients remotely and optimize their treatment.

A secondary set of segments are then the actual buyers of the product. Here we are considering the following three segments that would purchase the product for different reasons:

Group Contribution

1. Insurance providers, both private and public, will reimburse the purchase of the product as part of the treatment of one of their customers.
2. Government hospitals and health services buy the product through public procurement procedures in larger volumes to apply in their operations.
3. Individual CKD patients, regardless of their current treatment, buys the device for themselves to better follow their disease.

TARGET SEGMENTS

For our first product, the SIKMA, we have decided to focus among the buying segments on individual CKD patients. The segment of individual diagnosed CKD patients consists of 37 million people in the U.S. market (National Kidney Foundation 2022, National Kidney Foundation 2022). It is characterized as having the fastest and least formal buying process among the proposed segments. The consumers are adults and are struggling to manage their CKD. They are moderately sensitive to price considering the potential impact on their everyday life, where CKD is starting to take its toll mainly on their psyche, where they seek to get more autonomy.

To address this segment, our promotional activities need to cater additionally to the medical professionals, which enables our customers to buy the SIKMA with a prescription. A prescription or reference from a medical professional is crucial, as this allows our customers, the CKD patients, to seek reimbursement from their insurance provider. Around 68% of all Americans are covered by private health insurance-, while the remaining 32% are covered by the government programs Medicare and Medicaid (Mordor Intelligence 2022). The private market consists of 907 companies (Stasha 2022), where the leading 25 companies are responsible for 60% of the total market value (Mordor Intelligence 2022). In summary, the

Group Contribution

segment contains the CKD patient as the purchase decision-maker and partial buyer, the medical professional as the enabler of the purchase, and lastly, the insurance provider as the indirect payer through reimbursement.

We have decided not to directly target government entities within the health sector, as they are characterized by more prolonged and formal processes for making purchasing decisions through tenders and are affected by public procurement laws, where it might be challenging to find a fit for our device initially. Therefore, we aim to utilize the selected segments to create awareness in the market and start building a reputation around our product and the science behind it.

POSITIONING

Looking at the current market, we see ample freedom to position our product. From the existing market and feedback from potential users, we see the main factors as being Completeness and Invasiveness, which we define as the following:

Completeness: We define it as the product or service's ability to cover the entire process from collecting data to prognosis and presenting it to the patient and the medical team. Partial products only offer elements of this process.

Invasiveness: The need for the invasive collection of samples to obtain data. Blood samples are the most invasive (worst), and reverse iontophoresis is the least invasive (best).

Group Contribution

Preventico aims to enter the area of being non-invasive and an all-in-one product that facilitates everything from collecting data to presenting it and a prognosis to patients and their medical team (see Figure II).




Figure II: Positioning of the SIKMA by Preventico in the competitive landscape

MARKETING PLAN

VALUE PROPOSITION

SIKMA will have three value propositions for the different stakeholders:

CKD patient: we want to provide CKD patients with the best quality of life possible, allowing them freedom of choice in their everyday lives. We collected several testimonials from CKD patients during our active search in the kidney disease market. From the CKD patients' interviews, we were able to understand that one of their main constraints was the lack of

Group Contribution

independence they felt in their day-to-day lives, as they did not have constant monitoring of elements that are crucial for their well-being, such as phosphorus, potassium or sodium levels, three examples of minerals that can build up to unsafe levels in the bloodstream when kidneys are not functioning correctly, leading to heart attacks, for example. These patients mentioned that for them to have more quality of life, it would be essential to track these levels continuously, which would allow them to live less restricted, knowing what type of food they can eat or how much fluids they can drink every moment, promoting autonomy and independence. SIKMA will enhance disease management and allow to slow/stop the deterioration of kidney function. As a patient mentioned: “anything that can alleviate the issues and make each day a better day would be absolutely fantastic.”

Healthcare professional: SIKMA will offer optimal treatment, less need for checkups, fewer unnecessary consultations, saving time on checkups, and making it easier for patients to stick to a treatment plan. Additionally, SIKMA will allow for intelligent scheduling of patients according to the severity of patients’ health status. Less frequent check-ups enable doctors to have more consultations with other patients, and collecting data in an automated way (that would happen in a typical doctor’s visit) has the potential to give a patient more face time with the doctor. Moreover, as doctors will have the opportunity to do remote monitoring of patients’ healthcare status, they can also opt for telemedicine instead of in-person consultations. In addition, with access to more consistent and accurate patient health data, healthcare professionals can intervene as soon as there is a problem to help prevent costly complications, ER visits, and hospital admissions.

Furthermore, nowadays, the healthcare sector is shifting towards value-based reimbursement models rather than volume-based care, meaning that healthcare providers are paid based on the quality of the care provided and not on the number of tests and procedures they order (fee-for-

Group Contribution

service care). Currently, in the U.S., value-based programs are rewarding providers for the quality of the care provided to Medicare beneficiaries. As such, the SIKMA will serve as an asset for healthcare professionals allowing them to reduce costs and eliminate redundant care and hospital visits through continuous monitoring of their patients' healthcare status. With this paradigm shift from volume to value, the SIKMA will also contribute to decreasing healthcare professionals' burnout since the fee-for-service model is characterized by a high volume of documentation, leading to doctors spending time and energy doing administrative work.

Insurance provider: the SIKMA will generate cost savings and cheaper treatment, as medical costs attributable to CKD are substantial among Medicare beneficiaries. Since these costs increase as the disease severity worsens, our product will allow for an early intervention to help slow the progression of CKD and prevent patients from progressing into later stages of the disease, where they would need hemodialysis or kidney transplant, resulting in high costs savings. Such savings will also be generated through less frequent blood tests since patients will have continuous monitoring allowing for a close follow-up without needing an appointment. Additionally, insurers will be able to reduce the rising cost per patient, as using SIKMA will reduce the need for hospital visits and readmissions due to poorly managed personal health.

PROMOTIONAL ACTIVITIES

We will advertise the SIKMA through several promotional activities, which will include:

- Medical trade shows, expos, and congresses, allowing other experts in the wearable biosensors industry and medical doctors to put a face to the product and showing to our peers how the SIKMA works:

Group Contribution

- The **Chronic Kidney Disease Drug Development Summit, Boston** (only industry-driven event dedicated to accelerating the edge of preventative and regenerative therapies to target kidney disease, being the single end-to-end convention presenting scientific advancements as actionable insights);
- **DeviceTalks Boston** (unites MedTech's most innovative professionals and helps companies overcome troublesome bottlenecks in several critical stages, such as prototyping & product development, manufacturing & sourcing, and engineering tools and technology);
- **BIOMEDevice, Boston** (brings together recognized leaders, top global researchers, medical professionals, and innovators in healthcare, biotechnology, and MedTech sectors to showcase emerging technologies and trends that will push forward the medical device industry).
- Thought leadership: invite recognized leaders in both nephrology and wearable biosensors fields to provide state-of-the-art contributions about the SIKMA.
- Advertise it through The National Kidney Foundation and other patient support groups through product endorsement patient-to-patient.
- Interviews on relevant healthcare podcasts with established audiences.
- Advertisement through social media accounts.
- Articles written by our scientific team that highlights the SIKMA's benefits for CKD patients.
- Company events to generate awareness among the scientific community about our product's benefits and potential adoption by medical doctors.

FINANCIAL SITUATION

FINANCIAL FORECASTING

As shown in Figure V, we will not be able to generate profits or produce goods before we obtain FDA clearance in 2030, because we need to focus on the development of SIKMA in order for the product to obtain FDA clearance and be allowed for sale. We expect our revenue to increase from \$16.2 billion in 2030 to \$64.8 billion in 2031 after we start selling in the domestic market. This can be explained by the fact that we have planned to expand into Europe in 2031.




Figure V: Annual cashburn in USD

The approval process for SIKMA and the associated clinical trials are time-consuming and costly, which explains why we are dependent on external funding to reach the next milestones. Figure VI shows the annual cash burn rate, which indicates that we will not generate revenues in seven years, even though we have already started developing the prototype and conducting the clinical trials.




Figure VI: Revenue develop of Preventico over a 10 year period

INVESTMENT CRITERIA FOR MEDTECH STARTUPS

To give a deeper insight into our funding strategy and potential investors, it is important to go into the investment criteria of investors in MedTech startups. Increased financial risk is taken by many VC investors due to their passion for the MedTech/healthcare sector. Reducing the financial risk as an investor by investing in MedTech startups and getting the maximum return on investment requires the following criteria to be fulfilled:

Strong management team: as described in our team section, we can leverage our years of experience and expertise in the kidney disease market and build a successful startup.

Scalable technology: Our wearable device will not only be applicable for monitoring biomarkers in CKD patients but also for patients suffering from other chronic diseases, such as diabetes. This will enable us to meet an unmet need in large markets.

Cutting the high costs of health care: A large proportion of VCs consider the approach that MedTech startups succeed in reducing costs in the healthcare sector through their breakthrough innovation to be interesting. Wearing our smartwatch would help save CKD patients USD 1.1Bil over 5 years per 100k patients in case of early diagnosis.

Visionary company that focuses on efficiency: VCs have a preference for strategic founders who build a profitable business with fewer resources. We have two founders with experience in strategy who have had to learn how to reduce costs and build cost-effective business models. This expertise is particularly important when we need to provide clinical evidence, develop a commercialization plan and protect our intellectual property.

SOURCES OF FUNDING

Start-ups in the field of medical devices have alternative strategies for raising capital besides traditional funding opportunities such as government grants or venture capital. For Preventico in particular, the first priority is to bring SIKMA to market efficiently. Since the development from concept to the market launch of the wearable biosensor is associated with high costs, raising capital is necessary at every stage (Igoe 2021). In addition to the continuous liquidity of our start-up, the selection of the right investors is necessary. Specifically, we expect our seed-stage investors to contribute with their expertise in the development of a medical non-invasive monitoring device and to work with us to develop clinical pathways that will raise physicians' awareness of the need for timely intervention and prevent the possibility of costly hospitalizations. (Fresenius Medical Care North America 2019).

We have planned to fund Preventico for the next 10 years, mainly through the American Seed Fund (SBIR), Government Grants, corporate venture capital, and venture capital fund. Other potential funding sources such as SPACs, MedTech incubators, family offices, or business

angels, which have gained popularity among MedTech startups in recent years, will not be considered for strategic reasons.

Special Purpose Acquisition Companies (SPACs) are shell companies that are established for the sole purpose of raising investor funds when they go public (Deutsche Startups 2021). They are used by MedTech startups as a fundraising tool to secure capital in the public markets at a very early stage. As a result, startups have wider access to the investor pool, even if no revenues are generated (Deloitte 2017). Nevertheless, SPACs have the disadvantage that they have to close an acquisition within two years or be obliged to return the funds back to the investors. Elizabeth Cairns, a MedTech reporter, warns that especially now, the market conditions are volatile, and therefore MedTech startups should consider other financing instruments. (Condon 2022).

Compared to SPACs, MedTech Incubators and Accelerators are not dependent on market events as a financing instrument and are often viewed as institutions that provide startups with support which has as its primary goal to give training to founders rather than providing them with financial resources. Some accelerators even provide funding. The big advantage of incubators compared to traditional funding methods is the network, training, and experience founders receive. Especially when it comes to raising capital, founders receive valuable support in finding suitable investors and learning the language of investors. As a result, founders have a substantial competitive advantage over other startups (Igoe 2021). An example of a MedTech accelerator is the program offered by the Mayo Clinic and Arizona State University for Healthcare. Specifically, the Accelerator helps medical device companies with a focus on healthcare technologies by offering customized commercial plans to boost the MedTech startup's time to market and investment opportunities (MedTech Accelerator 2022).

OUR FUNDING STRATEGY

The figure shows that in the first financial year of 2023, we will fund Preventico mainly with non-dilutive financing methods such as The Small Business Innovation Research Program (SBIR) and Nephure Kidney's NEPTUNE Ancillary Studies Grant Program. Non-dilutive funding provides the great advantage over other funding options in that no stakes have to be given up by the company, and the money does not have to be paid back (Dykeman 2019). All scientists are eligible to apply for Nephure Kidney's NEPTUNE Ancillary Studies Grant Program. By passing through a competitive process, Preventico would receive \$150,000 to cover part of the cost of prototype finalization (NephCure Kidney International 2022). The Small Business Innovation Research Program of America's Seed Fund is one of the largest sources of non-dilutive funding capital (Dykeman 2019). To be eligible for SBIR, Preventico must meet the following criteria when applying: we must strive for a profitable business model, have less than 500 people employed by us, and be headquartered in the U.S. (National Science Foundation 2018). As grants provide good financial support for the beginning of our business, this type of financing is not sustainable and is therefore only a temporary solution. (S3 Solutions 2021). However, they are very helpful for us as they increase our credibility and thus provide the bridge to our seed investors. In total, we would raise \$375,000 in 2023 if our application is successful.

For FY 2024, we have planned to raise \$9Mil in seed funding from the following VC funds: Digitalis Ventures, Sky Ventures Group, and the National Kidney Innovation Fund. The report "Healthcare Investment and Exits" by Silicon Valley Bank has concluded that venture capital remains a popular form of funding for medical device startups (Silicon Valley Bank 2022). Partly this is due to the fact that capital is provided without having to make any interest and redemption payments (The Hartford 2022). Start-ups not only benefit from the capital provided

but also from their expertise in bringing a new type of media device to the market. The biggest and most important advantage of venture capital compared to other financing methods is that VC investors are very well connected in the industry and can actively support, for example, start-ups in the development of their IP strategy. (The Hartford 2022). However, as founders, we have to bear in mind that we are under an enormous form of due diligence and have to achieve certain milestones on metrics in agreement with the capital providers. (Rutledge 2022). As one of our seed investors, Sky Ventures is particularly well qualified to enter Boston in the early years and benefit from the healthcare ecosystem because it provides funding to life sciences and early-stage healthcare companies. In particular, Sky Ventures differentiates itself from other VC funds through its extensive network of strategic partnerships, which currently includes 35 strategic partners. (Sky Ventures 2022). The National Kidney Innovation Fund is also a key investor in our seed funding phase. The NKF Innovation Fund is an investment initiative that seeks to invest in early-stage startups that pursue the mission of enabling CKD patients to live more productive lives. NFK could provide support to Preventico with their knowledge in topics such as reimbursement, regulatory pathways, and patient preferences, so that our medical device is ready to receive FDA approval and will be commercially available in the near future (National Kidney Foundation 2022).

For FY 2026, we have planned to raise \$15 Million in a Series A funding round from the following investors: Fresenius Medical Care Ventures (CVC), Boston Scientific, Sonder Capital and Shangbay Capital. Fresenius Medical Care holds a leading position in the field of renal care products and related services (Fresenius Medical Care North America 2019). As of 2016, it runs its own corporate venture capital fund, Fresenius Medical Care Ventures. Under this fund, the company invests in early-stage start-ups. Its focus is on early-stage start-ups and companies operating in the healthcare industry that are dedicated to creating products and technologies for therapies in the area of diabetes, CKD, and cardiovascular disease (Fresenius

Medical Care Ventures 2022). Corporate VC has become more relevant in recent years among large pharmaceutical and medical technology companies as they have established their own corporate VC funds. Their mission is to invest in early-stage start-ups whose groundbreaking technology is in line with the strategic direction of their company. This has the implication that by running their own corporate VC fund, companies can massively increase their own innovation performance (Dykeman 2019).

Thanks to Fresenius Medical Care Ventures, Preventico would gain access to a well-known network and contribute to making SIKMA market-ready. In addition, this strategic investment offers another path to a successful acquisition. This topic is discussed in more detail in the exit strategy part. Fresenius Medical Care Ventures previously invested in BioIntelliSense in 2019, which released a wearable device that allows patients to be monitored remotely. The experience and insights from this deal would provide us with tremendous support in our product development. (Fresenius Medical Care North America 2019). According to Silicon Valley Bank's Healthcare Investments and Exit Report 2021, Sonder Capital and Shangbay Capital are among the most active investors in the new device space in the US and Europe. (Silicon Valley Bank 2022). Their expertise in building a medical device startup would help us efficiently navigate our way to FDA approval.

For FY 2028, we have planned to raise \$20 million in a Series B funding round from the following investors: Google Ventures (CVC), Versana Capital, Alumni Ventures Group, and RA Capital Management. Both Versana Ventures and Alumni Ventures Group were listed in the report by Silicon Valley Bank as one of the most active device investors (Silicon Valley Bank 2022). Such investors, who have experience in building medical device companies, are particularly important to have on board, as medical devices, in particular, are associated with many regulatory hurdles, and these investors know exactly how to overcome such challenges

successfully. Google Ventures is one of the most important investors in this round, as we intend to be acquired by Google Ventures in our exit year. Our exit strategy is explained in the "Exit Strategy" section.

For FY 2030, right after getting the FDA approval, we have planned to raise \$25 million in Series C funding round from the following investors: kck Medtech, Perceptive Advisors, and Softbank. In particular, both kck Medtech and Perceptive Advisors are known to invest in late-stage MedTech startups based on their deal history (kck medtech 2022). With their expertise, they would support Preventico in the launch of SIKMA.

Year	Stage	Investment size in \$	Investors
2023	Pre-seed	\$375.000,00	NephCure, America's Seed Fund
2024	Seed	\$9.000.000,00	Digitalis Ventures, Sky Ventures Group, National Kidney Innovation Fund
2025			
2026	Series A	\$15.000.000,00	Fresenius Medical Care Ventures (CVC), Boston Scientific, Sonder Capital, Shangbay Capital
2027			
2028	Series B	\$20.000.000,00	Google Ventures (CVC), Vensana Capital, Alumni Ventures Group, RA Capital Management
2029			
2030	Series C	\$25.000.000,00	kck Medtech, Perceptive Advisors, Softbank
2031			
2032			
2033	Exit		Google, Rockley Photonics

Table III: Funding sources and timing

RISKS IN SECURING EARLY-STAGE FUNDING

Twenty years ago, it was possible for a MedTech startup to exit within five years of its founding because strategic investors would buy out after it was approved by the FDA rather than after the medical device was reimbursed. In recent years, large strategic investors have realized that the path to reimbursement is a huge hurdle for MedTech startups and will only acquire once the medical device is reimbursed by the Centers for Medicare & Medicaid Services (CMS) (Deloitte 2017).

Karema Haschemi, 46378

For many MedTech start-ups, getting the right investors in the early stages and securing early-stage investment presents a major challenge. According to Andreas Wüpper, Investment Director of Fresenius Medical Ventures, we as founders of Preventico have to be prepared for the following risks in the process of securing funding:

Investors investing in MedTech startups are more conservative than startups involved in biopharmaceuticals. The reason for choosing to invest in MedTech startups is that investors expect a sophisticated commercialization plan from MedTech startups, clearly explaining the distribution channels through which we sell SIKMA. Another challenge for Preventico is going to be the inconsistent and opaque regulatory process. As the regulatory process has a certain level of opaqueness, it will be unpredictable and costly in terms of time for us. Currently, regulators are working on the flexibility and transparency of this process to provide more flexibility in the evaluation of new technologies eventually. Recently, the FDA published an action plan on how to evaluate software as a medical device (SaMD). Securing reimbursements is going to be the most difficult challenge for Preventico, since coding and reimbursement channels for medical devices that are not based on a traditional technology do not fall under the existing coverage guidelines. As this applies to Preventico, we will need to prove the acceptability of our product and apply for a new reimbursement code. The final decision for reimbursement is entirely up to the payer. The process, from the application for a new code to the assumption of the costs, delays the process of exiting enormously.

CAPITALIZATION TABLE

A capitalization table documents the ownership structure and indicates the path to financing rounds and exits. Using this spreadsheet, it becomes transparent and straightforward which shareholders are holding how many shares in Preventico. (Silicon Valley Bank 2022). Cap table

represents a crucial due diligence document for our prospective investors. It allows them to ensure that we as founders own enough for them to align their interests with our founding team (AngelList Venture n.d.). Moreover, it signals to investors how high the founders' incentive is for the startup and can guarantee that there is sufficient remaining equity to attract new investors in later rounds (Silicon Valley Bank 2022). Besides being beneficial for the investors, it is also crucial for us as a founding team.

Raising funds: For discussions with investors about a new financing round, the cap table provides us with a good overview of how Preventico's ownership is structured. Furthermore, it offers a good foundation for major decisions such as the issue of new shares or stock option pools and for informing investors about the impact of new financing rounds on their existing investments (Corporate Finance Institute n.d.).

Hiring employees: Like many other start-ups nowadays, we want to make sure that we are transparent with our employees about the cap table. This ensures that we can keep high-performing talent in the company, even if we run into financial difficulties. If the scenario occurs that we sell or liquidate Preventico, employees who own shares in the company will know what payouts they will receive. (Corporate Finance Institute n.d.)

Tax and Regulation Compliance: Since cap tables serve as legal proof of equity ownership in the United States, tax authorities in the United States can find out whether the company, its employees, and its investors are all paying the correct tax amount. If the scenario occurs that we fail to keep the cap tables updated, either Preventico and its employees will pay more tax than required, or we would pay hefty fines for reporting less tax than required.

As you can see from the simplified cap table below, all four founders own 25% of Preventico each. We have decided on an evenly split equity as we strongly believe that all four of us as

Karema Haschemi, 46378

founders will strongly contribute to taking Preventico to the next level. Not only do we as founders prefer this split, but a large number of investors recommend a balanced split among the co-founders.

EXIT STRATEGY

For a successful exit, we have planned to sell Preventico to a strategic investor in the form of an acquisition in the fiscal year 2033. The duration of our start-up until our exit is in line with the majority of exits of 7-10 years with medical device start-ups (Deloitte 2017). João Santos Pereira, who sold his startup HeartGenetics to TomaLab in 2020, advises us for Preventico's exit to keep the basics in mind: determine a target market, have a strong intellectual property strategy, and use the raised funding responsibly (Newmarker 2020).

Big tech giants such as Apple and Samsung have already invested large amounts of capital in companies developing non-invasive sensors. Rockley Photonics, the maker of biosensors featured in the Apple Watch, announced in July 2021 that it is working on a new generation of health sensors by enabling non-invasive blood glucose measurement (Reader 2022). Given that Apple is already working with Rockley Photonics on a medical device that allows patients & consumers to be monitored from home and Samsung Ventures has also invested in a startup that measures blood glucose levels in a non-invasive way, we are confident that being acquired by Google is a winning strategy (Diamontech 2022). Google has already acquired Fitbit, a pioneer in the fitness band market, for \$2.1 billion in 2019 and is releasing its first smartwatch, the „Google Pixel Watch,“ this autumn. (Peckham 2022). Based on these two strategic decisions, it becomes clear that Google's vision consists of having a universal smartwatch that knows everything about your health. This vision is very much in line with our version, which is why we are sure that selling to Google in 2033 will be the best strategy to maximize our exit

valuation. A strong IP portfolio and potential synergies make Preventico an attractive target for large strategic investors like Google in the tech and MedTech industry. This strategy leads to synergies, such as economies of scale or scope, by integrating operations or business lines. This exit strategy has the advantage that the strategic buyer will pay a greater price. Furthermore, this exit strategy has a more straightforward diligence process in general – less focus on short-term financials, typically no commercial diligence, and less risk of a last-minute price shift (Isosceles Finance 2022).

For many early-stage investors, the ultimate goal is to invest in companies that eventually grow large enough to have an Initial Public Offering (IPO) (Sharp 2022). Among the reasons for the IPO as an exit strategy is the higher valuation and increased liquidity from selling the remaining shares after the IPO. With their increased liquidity, MedTech startups would continue to grow as a company by acquiring other businesses and investing in research and development (Hunsaker 2017). In this way, they can ensure that they maintain their ability to innovate as a company and remain competitive in the future. A crucial factor in favor of an IPO is the support from the management team, as they know that they will keep their positions after the IPO, as opposed to a strategic acquisition. However, we have decided against this exit strategy because it is time-consuming and associated with high costs and regulatory obligations. As there is no complete exit possible, it is likely that the market will react negatively after the IPO and get fewer funds to exit (Hunsaker 2017).

TIMELINE & KEY MILESTONES

Bringing SIKMA to market involves several challenges that significantly extend the commercialization process. Such challenges would arise, among others, if there is a mismatch with the regulatory authorities or if the raised capital is burnt quickly. These types of risks would lead to a drastic loss in the valuation of Preventico (htt). Over the next few years, the key milestones will be the various funding phases that will increase Preventico's enterprise value. Investors only choose to invest in Preventico when we are about to reach a particular milestone and need the necessary capital to do so (Arnold 2021).

After defining our clinical needs and conducting extensive market research and assessment of the potential size of the market, we will apply for the America's Seed Fund The Small Business Innovation Research Program (SBIR) and the Nephure Kidney's NEPTUNE Ancillary Studies Grant Program in 2023. In total, we would get \$375,000 if our application is successful. In the early years, we focus heavily on the completion of a prototype, together with our Research & Development team. Once our proof of concept is in place, we work with the law firm Cooley LPC, which provides expertise in patenting medical devices, with the goal of developing an IP strategy and submitting our patent application.

Our proof of concept helps us to secure the first investors (Digitalis Ventures, Sky Ventures Group, and the National Kidney Innovation Fund) for our 10 million seed round in 2024. We will allocate this money to expand our team with several employees who are necessary for the development of the software. These would be the following roles: two Embedded Software Programmers, two Junior Developers, one Senior Project Manager, one DevOps, one Data Scientist, and one Optic Specialist. While selecting suitable candidates for our team, we begin our preclinical studies to predict treatment outcomes in patients and detect potential toxicities.

Group Contribution

(R.S.Ness 2022). We will seek regulatory approval in the US, Europe, China, and Japan before we start our clinical trials to ensure that SIKMA is registered in these countries as well. Conducting clinical trials is associated with high costs, which is the reason why we seek to raise xx in Series A funding from the following investors: Fresenius Medical Care Ventures (CVC), Boston Scientific, Sonder Capital, and Shangbay Capital. Besides the funding amount, we ensure that our clinical expert, who manages the clinical trials, keeps the costs within reasonable limits. During our clinical studies, we file submissions with the FDA, seeking clearance for our wearable device SIKMA. We are seeking FDA approval at this stage primarily because we are targeting the domestic market first, and over the years, we will obtain the CE marking. Briefly, after we announced the results of our clinical study showing that the accuracy of our method for non-invasive measurement of biomarkers in CKD patients is confirmed, we will receive a 510 (k) clearance from the U.S. FDA in 2029.

In 2030, right after we got the FDA approval, we have planned to raise \$25 million in Series C funding round from the following investors: kck Medtech, Perceptive Advisors, Softbank. With the raised capital we would like to expand our team by hiring a majority of sales representatives and allocate the remaining funds for the production of SIKMA and the planned marketing activities such as expos and conferences within the health industry. We will hand over the production and design of SIKMA to the Danish manufacturer Cre8tek Denmark Aps. We will obtain regulatory approval to register SIKMA in the US, Europe, China, and Japan. At the beginning of 2030, we will start with the first sales in the USA. Securing reimbursements is going to be the most difficult challenge for Preventico, since Coding and reimbursement channels for medical devices that are not based on a traditional technology do not fall under the existing coverage guidelines. As this applies to Preventico, we will need to prove the acceptability of our product and apply for a new reimbursement code in 2030. We expect to obtain our Common Procedural Terminology (CPT) reimbursement code by the end of 2030.

Group Contribution

In early 2032, we expect to reach our break-even point and stop relying on investors for future cash injections, and will expand to Europe, China, and Japan. Our reason for expanding to China and Japan is based on the latest results from The Insight Partners report. They concluded that Asia-Pacific is one of the fastest-growing regions. In Japan and China, in particular, we are seeing growing interest from investors in kidney disease (Bloomberg 2021).

For a successful exit, we plan to get acquired for \$190 million by Google in 2033. While preparing for our exit process, we need to focus on providing data to Google's investors to ensure that we are among the top medical device startups.

As founders of Preventico, we are aware that at every stage of our venture, we need to have qualified advisors and experts at our side who are familiar with the legal requirements. This is the only way to guarantee that we can save money, and time, and ultimately reduce the risk of patient suffering when SIKMA is available on the market.

CONCLUSION

CKD affects 37 million Americans every single day, and Preventico will make their lives easier by introducing the SIKMA, a new wearable device that measures key values for a CKD patient and thereby gives them greater autonomy and quality of life. The SIKMA also creates value for the patient's medical team, as it allows them to follow the patient remotely and manage their disease treatment plan based on an updated health status.

The SIKMA combines groundbreaking research in the field of biomarkers and the ability to measure them using ISF. Today the product is at the proof-of-concept stage, but in the coming two years, Preventico will undertake the process of developing a working prototype and accompanying software, with the manufacturing process being outsourced to a key partner, while software development will remain in-house to keep control of the user experience. The final product will offer a novel all-in-one solution with its ability to measure, present and prognosis a CKD patient, which generates value for both patients, doctors, and insurance providers. We will pursue an aggressive IP strategy to ensure that the value of the developed product is secured within the company with filings both in the U.S. and the rest of the world leveraging the PCT.

The U.S. is one of the nations with the largest healthcare expenditure overall, with significant costs incurred for the treatment of CKD patients, with large parts of these incurred by the federal Medicare program. The U.S. is undergoing a trend where the focus is moved from quantity to quality in the remuneration of medical professionals. The SIKMA ties into that trend, as it has the potential to create a higher quality of care for patients and lower the number of admissions to the ER, critical care, and general medical consultations.

Group Contribution

With the market for products such as the SIKMA, only a small number of direct competitors are present, although substitutes and alternatives do exist. Compared to these, the SIKMA will enter a unique position by providing the most non-invasive way of gathering data while still facilitating the entire progress from data collection to final prognosis.

In our marketing efforts, we have identified the key person to convince as being medical professionals, as these have the power to facilitate the reimbursement of the costs of our product from insurance providers, the indirect payers, and present our product to the suitable patients, our users. To reach these audiences, Preventico will be present on digital channels and at recognized expos and conferences within the health industry. We will also be leveraging our R&D to be present throughout academic and scientific journals. The end goal is to have the product spread by word of mouth among CKD patients.

Preventico is on an ambitious track to create a single device for your wrist that can keep you up to date with your health status at a glance. The founding team consisting of Madalena Lara, Karema Haschemi, Sigurd Koldste, and Paulo Zoio will leverage their existing experience and knowledge to fill out the executive roles of CCO, CFO, CEO, and CSO. In addition to the founders, we will rapidly expand the team to strengthen our expertise in software development by recruiting for numerous roles within the early stages of the company, so we can bring the SIKMA to market.

Since the development from concept to the market launch of SIKMA is associated with high costs, raising capital from the right investors is necessary at every stage. We expect our selected investors to contribute with their expertise in the development of a medical non-invasive monitoring device and to work with us to develop clinical pathways that will raise physicians' awareness of the need for timely intervention and prevent the possibility of costly hospitalizations. We have planned to fund Preventico for the next 10 years mainly through the

Group Contribution

American Seed Fund, government grants, corporate venture capital, and venture capital, and expect that we will raise a total of \$69.4 million in funding. However, we need to be prepared for upcoming risks in the process of securing funding, like the opaque regulation process or the challenge of securing reimbursement. All these obstacles are causing delays and high expenditures in the process of commercialization of SIKMA. By keeping close track of our capitalization table, where the ownership structure is documented, we ensure that we have a good overview of which shareholders hold how many shares in Preventico. All four founders have decided on an evenly split equity as we strongly believe that all four of us will strongly contribute to taking Preventico to the next level. For a successful exit, we have planned to sell Preventico to Google for \$190 million via a strategic acquisition in 2033.

Bringing the SIKMA to market involves several challenges that significantly extend the commercialization process. Such challenges would arise, among others, if there is a mismatch with the regulatory authorities or if the raised capital is burnt quickly. Among the key milestones are the patent filings, receiving a 510 (k) clearance from the FDA in 2029, and obtaining our Common Procedural Terminology (CPT) reimbursement code by the end of 2030.

Looking into the future of healthcare, we want to provide the possibility for anyone to know everything about their health with just a quick glance at the wrist.

REFERENCES

AngelList Venture. n.d. Accessed 2022. <https://learn.angellist.com/articles/cap-table>.

Arnold, Rocky Richard. n.d. <https://www.linkedin.com/pulse/roadmap-introducing-new-medical-devices-part-vi-company-arnold-1f/>.

—. 2021. March 09. <https://www.linkedin.com/pulse/roadmap-introducing-new-medical-devices-part-vi-company-arnold-1f/>.

AstraZeneca. 2020. *Chronic kidney disease: a patient story*. March 11.

n.d. <https://rs-ness.com/roadmap-of-medical-device-company-from-idea-to-the-market/>.

Bloomberg. 2021. *Kidney Disease Market Size Worth \$133,444.71 Million, Globally, by 2027 at 6.5% CAGR - Exclusive Report by The Insight Partners*. December 15. Accessed April 2022. <https://www.bloomberg.com/press-releases/2021-12-15/kidney-disease-market-size-worth-133-444-71-million-globally-by-2027-at-6-5-cagr-exclusive-report-by-the-insight-partners>.

Boston University. 2009. *Biomarkers of Disease*. Accessed May 18, 2022. <https://www.bumc.bu.edu/evanscenteribr/the-arcs/graduated-arcs/biomarkers-arc/>.

Brophy, Kieran, Samuel Davies, Yasin Çotur , Selin Olenik, Damien Ming, Nejra Van Zalk, Danny O’Hare, Firat Güder, and Ali Yetisen. 2021. *The future of wearable technologies*. Briefing Paper, London: Imperial College London: Institute for Molecular Science and Engineering.

Group Contribution

Centers For Disease Control and Prevention. 2022. *Chronic Kidney Disease Initiative*. February 28. Accessed April 2022. <https://www.cdc.gov/kidneydisease/basics.html>.

Centers for Medicare & Medicaid Services. 2021. *Medicare Coverage of Kidney Dialysis & Kidney Transplant Services*. Baltimore, December.

Cohen, Marissa. n.d. <https://www.svb.com/startup-insights/raising-capital/understanding-startup-cap-table>.

Condon, Alex. 2022. May 09.

Cooley LLP. 2022. "Cooley Protect." *Intellectual Property Review Committee*. Accessed May 16, 2022. <https://www.cooley.com/-/media/cooley/protect/cooley---ip-review-committee.ashx>.

—. 2022. *FAQ: Provisional Patent Applications*. Accessed May 16, 2022. <https://www.cooley.com/protect/2020/03/10/frequently-asked-questions-provisional-patent-applications>.

—. 2022. *Protecting Your Company's Intellectual Property*. Accessed May 16, 2022. <https://www.cooley.com/protect/2020/02/28/protecting-your-companys-intellectual-property>.

Corporate Finance Institute. n.d. Accessed 2022. <https://corporatefinanceinstitute.com/resources/knowledge/valuation/cap-table-guide-template/>.

Group Contribution

Damien, Paul, Holly J. Lanham, Murali Parthasarathy, and Nikhil L. Shah. 2016. "Assessing key cost drivers associated with caring for chronic kidney disease patients." *BMC Health Services Research*, December 28.

Daso, Frederick. 2019. "Healthcare Startup pulseData Raises \$16.5M To Help Lower Costs To Treat Kidney Disease." *Forbes*, April 19.

Deloitte. 2017. "New strategies for medtech startups."

Deutsche Startups. 2021. May 6. <https://www.deutsche-startups.de/2021/05/06/spacs-startups/>.

Diamontech. 2022. February 17. <https://www.diamontech.de/pressemeldungen-en/diamontech-attracts-5-million-from-samsung-ventures-and-u-s-based-venture-capitalists-to-bring-its-new-non-invasive-glucose-monitor-to-the-u-s>.

Dick, John. 2018. *Live Chat Exposes a Fatal Flaw in Your Go-to-Market*. June 21. Accessed May 16, 2022. <https://blog.hubspot.com/sales/live-chat-go-to-market-flaw>.

DrKumo Inc. 2021. *Top 5 Remote Patient Monitoring Devices for People with Chronic Kidney Disease in 2022*. November 21. Accessed May 19, 2022. <https://drkumo.com/rpm-remote-patient-monitoring/top-5-remote-patient-monitoring-devices-for-people-with-chronic-kidney-disease-in-2022/>.

Dugdale, David. 2021. *Medline Plus*. 07 21. Accessed March 2022. <https://medlineplus.gov/ency/article/007305.htm>.

Dykeman, David J. 2019. July 30. https://www.mpo-mag.com/issues/2019-07-25/view_columns/funding-tips-to-help-medtech-startups-cross-the-valley-of-death/.

Group Contribution

—. 2019. July 30. https://www.mpo-mag.com/issues/2019-07-25/view_columns/funding-tips-to-help-medtech-startups-cross-the-valley-of-death/.

Edwards, Scott P. 2012. *Boston Hospitals - Curing disease, improving lives*. November. Accessed May 18, 2022. <https://www.harvardmagazine.com/2012/11/boston-hospitals>.

FDA. 2018. *FDA's Role in Regulating Medical Devices*. August 31. Accessed May 4, 2022. <https://www.fda.gov/medical-devices/home-use-devices/fdas-role-regulating-medical-devices>.

—. 2018. *The Device Development Process*. January 4. Accessed May 4, 2022. <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/device-development-process>.

Fortune Business Insights. 2022. *Global Medical Devices Market Size worth USD 657.98 Billion by 2028, Exhibiting a CAGR of 5.4%*. January 24. Accessed March 2022. <https://www.globenewswire.com/news-release/2022/01/24/2371389/0/en/Global-Medical-Devices-Market-Size-worth-USD-657-98-Billion-by-2028-Exhibiting-a-CAGR-of-5-4.html>.

Fresenius Kidney Care. 2022. *The Stages of Kidney Disease*. Accessed March 2022. <https://www.freseniuskidneycare.com/kidney-disease/stages>.

Fresenius Medical Care North America. 2019. September 07. <https://fmcna.com/company/our-company/news-releases/fresenius-medical-care-north-america-invests-in-biointellisense-/>.

Fresenius Medical Care Ventures. 2022. <https://www.freseniusmedicalcare.com/en/fmcev>.

Group Contribution

GBD Chronic Kidney Disease Collaboration. 2020. "Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017." *The Lancet*, February 13: 709-733.

Hidefjall, Patrik, and Dina Titkova . 2015. "Business model design for a wearable biofeedback system." *Studies in Health Technology and Informatics*, May: 213-224.

Hill, Nathan, Samuel Fatoba, Jason Oke, Jennifer Hirst, Christopher O'Callaghan, Daniel Lasserson, and Richard Hobbs. 2016. "Global Prevalence of Chronic Kidney Disease—A Systematic Review and Meta-Analysis." *PLOS ONE*, July 6.

Hunsaker, Morgan. 2017. November 28. <https://www.ipohub.org/ipo-advantages-disadvantages/>.

Igoe, Sarah. 2021. June 4. <https://jauntup.com/resources/this-is-how-medical-device-startups-are-raising-money-in-2021/>.

—. 2021. June 04. (<https://jauntup.com/resources/this-is-how-medical-device-startups-are-raising-money-in-2021/>).

Isosceles Finance. 2022. <https://www.isoscelesfinance.co.uk/considering-exit-type-buyer-hoping-attract/>.

Junior, Geraldo Bezerra da Silva, Luiza Jane Eyre de Souza Vieira, Marcel Rodrigo Barros de Oliveira, Eduardo Rocha Dias, and Juliana Gomes Ramalho de Oliveira. 2018. "Global costs attributed to chronic kidney disease: a systematic review." *Revista da Associação Medica Brasileira*, December: 1108-1116.

kck medtech. 2022. <https://www.kckmedtech.com/#Home>.

Group Contribution

Kim, Jayoung, Alan S. Campbell, Berta Esteban-Fernández de Ávila, and Joseph Wang. 2019.

"Wearable biosensors for healthcare monitoring." Author manuscript, San Diego.

Kristoffersson, Annica, and Maria Linden. 2020. "Wearable Sensors for Monitoring and Preventing Noncommunicable Diseases: A Systematic Review." *Information*, November 6.

Maciejewski, Matthew L, Karen Onstad, and Loida Tamayo. 2020. *Chronic Kidney Disease Often Undiagnosed in Medicare Beneficiaries*. Baltimore: Centers for Medicare & Medicaid Services Office of Minority Health, October.
<https://www.cms.gov/files/document/ckd-data-highlight102020-2.pdf>.

Mayo Clinic. 2021. *Blood urea nitrogen (BUN) test*. August 19. Accessed May 19, 2022.
<https://www.mayoclinic.org/tests-procedures/blood-urea-nitrogen/about/pac-20384821>.

McCullough, KP. 2019. <https://jasn.asnjournals.org/content/30/1/127.long>.

MedTech Accelerator. 2022. <https://www.medtechaccel.com/>.

Mordor Intelligence. 2022. *United States Health and Medical Insurance Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)*. Accessed May 19, 2022.
<https://www.mordorintelligence.com/industry-reports/united-states-health-and-medical-insurance-market>.

National Kidney Foundation. 2022. *GFR*. Accessed April 2022.
<https://www.kidney.org/atoz/content/gfr>.

Group Contribution

—. 2015. *Global Facts: About Kidney Disease*. March. Accessed May 17, 2022. <https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease>.

—. 2022. *Homepage*. Accessed May 19, 2022. <https://www.kidney.org/>.

—. 2022. *National Kidney Foundation*. Accessed March 2022. <https://www.kidney.org/atoz/content/peritoneal>.

—. 2022. *Newsroom*. Accessed March 2022. <https://www.kidney.org/news/newsroom/fsindex>.

—. 2022. *Peritoneal*. Accessed March 2022. <https://www.kidney.org/atoz/content/peritoneal>.

—. 2022. *Potassium and Your CKD Diet*. Accessed May 19, 2022. <https://www.kidney.org/atoz/content/potassium>.

National Science Foundation. 2018. December 04. <https://www.nsf.gov/pubs/2018/nsf18593/nsf18593.htm#:~:text=Successful%20applicants%20will%20receive%20a,months%20after%20the%20solicitation%20deadline>.

NephCure Kidney International. 2022. <https://nephcure.org/research/apply-for-research-grants/>.

Newmarker, Chris. 2020. March 03. <https://www.medicaldesignandoutsourcing.com/how-to-prepare-your-medical-device-company-for-an-exit/>.

Orsi, Tony, interview by Sigurd Koldste. 2022. *Memo: Correspondence with Tony Orsi* (May 18).

Palfrey, John. 2019. "2. Why Intellectual Property Matters." In *Intellectual Property Strategy*, by John Palfrey.

Group Contribution

Peckham, James. 2022. May. <https://www.techradar.com/news/google-pixel-watch>.

Pham, Thanh. 2021. *Analyzing The Software Engineer Shortage*. April 13. Accessed May 18, 2022. <https://www.forbes.com/sites/forbestechcouncil/2021/04/13/analyzing-the-software-engineer-shortage/?sh=745a593d321c>.

Puntmann, Valentina. 2009. "How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease." *Postgraduate medical journal*, October: 538-545.

R&D World. 2015. *The Future-as-a-Service*. October 30. Accessed May 18, 2022. <https://www.rdworldonline.com/the-future-as-a-service/>.

R.S.Ness. 2022. *Medical device roadmap from idea to market*. Accessed May 2022. <https://rs-ness.com/roadmap-of-medical-device-company-from-idea-to-the-market/>.

Reader, Ruth. 2022. March 11. <https://www.fastcompany.com/90730050/apple-partner-rockley-photonics-blood-sugar#:~:text=Rockley%20Photonics%2C%20the%20California%2Dbased,glucose%2C%20or%20sugar%2C%20levels>.

Renalytix. 2021. <https://investors.renalytixai.com/static-files/9d0b7860-2367-4c90-8ee7-be4fe2c9494d>.

Research and Markets. 2022. *Global Wireless Health and Fitness Devices Market Report 2022-2026: Rising Healthcare Costs Drives Focus on Wearables for Their Ability to Reduce Cost of Healthcare*. March 24. Accessed April 2022. <https://www.prnewswire.com/news-releases/global-wireless-health-and-fitness->

Group Contribution

devices-market-report-2022-2026-rising-healthcare-costs-drives-focus-on-wearables-for-their-ability-to-reduce-cost-of-healthcare-301509994.html.

Rutledge, David. 2022. Februar 3. <https://www.linkedin.com/pulse/how-medical-device-companies-raise-money-build-people-rutledge/>.

S3 Solutions. 2021. August 09. <https://www.s3solutions.co.uk/post/government-grants-advantages-and-disadvantages#:~:text=One%20of%20the%20biggest%20benefits,borrowed%20%2D%20often%20with%20added%20interest!>

Sharp, Adam. 2022. January 20. <https://republic.com/blog/investor-education/startup-exits-profits-explained#:~:text=An%20%E2%80%9Cexit%E2%80%9D%20is%20when%20a,after%20founding%2C%20or%20more.>

Shuey, Greg. 2015. *Like PB&J: Customer Service as a Marketing Strategy*. March 26. Accessed May 16, 2022. <https://www.business.com/articles/customer-service-as-a-marketing-strategy/>.

Silicon Valley Bank. 2022. "Healthcare Investments & Exits."

—. 2022. *Silicon Valley Bank - Startup Insights*. <https://www.svb.com/startup-insights/raising-capital/understanding-startup-cap-table>.

Sky Ventures. 2022. <https://www.sky-ventures.com/>.

Group Contribution

Smith, Mercer. 2021. *111 Customer Service Statistics and Facts You Shouldn't Ignore*. June 22.

Accessed May 16, 2022. <https://www.helpscout.com/75-customer-service-facts-quotes-statistics/>.

Sridhara, Sumukh. n.d. Accessed 2022. <https://learn.angellist.com/articles/cap-table>.

Stasha, Smiljanic. 2022. *How Many Health Insurance Companies Are There in the US? 2022*

Edition. March 5. Accessed May 19, 2022. <https://policyadvice.net/insurance/insights/health-insurance-companies-us/>.

Su, Jeb. 2018. *Apple Watch 4 Is Now An FDA Class 2 Medical Device: Detects Falls, Irregular*

Heart Rhythm. September 14. Accessed May 4, 2022. <https://www.forbes.com/sites/jeanbaptiste/2018/09/14/apple-watch-4-is-now-an-fda-class-2-medical-device-detects-falls-irregular-heart-rhythm/?sh=64e9828b2071>.

The Hartford. 2022. <https://www.thehartford.com/business-insurance/strategy/business-financing/venture-capital>.

U.S. Centers for Medicare and Medicaid Services. 2022. *Part B costs*. Accessed May 18, 2022.

<https://www.medicare.gov/your-medicare-costs/part-b-costs>.

—. 2022. *What's Medicare?* Accessed April 2022. <https://www.medicare.gov/what-medicare-covers/your-medicare-coverage-choices/whats-medicare>.

U.S. Department of Health & Human Services. 2013. *Summary of the HIPAA Privacy Rule*.

July 26. Accessed May 19, 2022. <https://www.hhs.gov/hipaa/for-professionals/privacy/laws-regulations/index.html>.

Group Contribution

—. 2022. *Your Rights Under HIPAA*. January 19. Accessed May 19, 2022.
<https://www.hhs.gov/hipaa/for-individuals/guidance-materials-for-consumers/index.html>.

United States Renal Data System. 2020. *2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States*. Annual Report, Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases.

Wieringa, Fokko Pieter, Natascha Broers, Jeroen Kooman, Frank Van Der Sande, and Chris Van Hoof. 2017. "Wearable sensors: can they benefit patients with chronic kidney disease?" *Expert Review of Medical Devices*, June 28: 505-519.

WIPO. 2022. *CHAPTER 3: THE INTERNATIONAL PHASE AND THE NATIONAL PHASE OF THE PCT PROCEDURE*. Accessed May 19, 2022.
<https://www.wipo.int/pct/en/guide/ip03.html#TopOfPage>.

—. 2022. *PCT Summary for new users*. Accessed May 19, 2022.
<https://www.c.int/pct/en/users/summary.html>.

Xu, Jing, Fang Yunsheng, and Jun Chen. 2021. "Wearable Biosensors for Non-Invasive Sweat Diagnostics." Basel.

APPENDIX

Appendix I - CKD patients interviews insights

During our problem discovery we interviewed 4 individuals that suffer from Chronic Kidney Disease, who are currently on hemodialysis, to gain deeper insights about how the disease affects their daily lives. The insights described below are anonymized.

- “I just found my kidneys were not filtering correctly when I had to do those routine blood tests because I competed at a high level in sports.” (Male CKD patient, 64 years old)
- “One of the signs is the blood pressure. The blood pressure and weight are related. If we have more fluids than what is our dry weight, the blood pressure will increase. But if we take out more fluids than the necessary the blood pressure will decrease. This would be an important indicator to measure during hemodialysis, so the nurses and doctors could know exactly the quantity of fluids the machine should extract.” (Male CKD patient, 58 years old).
- “There is also the measuring of potassium, phosphorous, calcium, urea. These are the parameters. I would say maybe something to measure potassium, sodium... But potassium is really important because if there are high levels one could just faint without knowing why. If we had something that could measure potassium, we could really know what kind of food we can eat at the moment that has a higher or lower content of potassium according to the exact levels at that time. If there was something that could measure potassium, patients could be less restricted as they would know what they could eat” (Female CKD patient, 36 years old)

Group Contribution


- “The dry weight for example, during hemodialysis. For the nurses and doctors to set the right dry weight, it is only possible for them to know they are taking too many fluids when we start feeling bad, the blood pressure drops, the person starts vomiting. On the other hand, if they leave a lot of fluids in the body our blood pressure shoots. It is a very hard equilibrium to find. I would really appreciate if it existed a way to know my dry weight without starting to feel sick (nausea, vomiting, cramps).” (Female, 36 years old)
- “Aside from this, measuring potassium would also be very important. Our diet is very restricted because of potassium and if we could measure it everyday we wouldn’t be so restricted. Me, being a CKD patient for so long, I already know how to recognize the potassium symptoms, such as lack of strength, muscle pain. With these symptoms I know I have to cut protein. But it is really difficult, it is a hard balance to reach. It would be important to know my daily levels of potassium so I could have more freedom to know that at that moment I can eat a certain thing or not. There is also the phosphorus issue. But we can fix it by taking medication to help remove it from the body. So, I would say the main concerns are the potassium levels and the dry weight.” (Female, 52 years old)

Group Contribution

Appendix II - Additional potential investors for the current and upcoming rounds

Investor	Location	Investment focus	Potential Series
Catalio Capital Management	Baltimore, Maryland, U.S.	biomedical technology companies (devices & diagnostics) globally	Seed
NEA (New Enterprise Associates)	Menlo Park, California, U.S.	2 sectors: tech (software, security, fintech, ecommerce, media) & healthcare (life sciences and digital health) globally; across all stages	Seed
Versant Ventures	Menlo Park, California, U.S.	biotechnology; globally; across all stages	Seed
OrbiMed Advisors	New York, U.S.	biopharmaceuticals, medical devices, diagnostics & healthcare services	Seed
Lightstone Ventures	Menlo Park, California, U.S.	biopharmaceuticals & medical technology; globally; across all stages	Series A
SV Life Sciences	Boston, Massachusetts, U.S.	biotechnology, dementia & medtech; across all stages	Series A
USVP (U.S. Venture Partners)	Menlo Park, California, U.S.	information technology, medical devices & biopharma; across all stages; globally	Series A
Ascension Ventures	London, England	healthcare information technology and services, medical devices and diagnostics; all investment stages; globally	Series A
Amed Ventures	San Francisco, CA, U.S.	medical device and medical technology globally	Series B
E-merge Capital Partners	San Diego, California, U.S.	early-stage medical device (class 2) companies and technologies	Series B
BioVenture	Suzhou, Jiangsu, China	biopharma, medtech, IVD, health services; across all stages; globally	Series B
Treo Ventures	Santa lara, California, U.S.	medical device & digital health innovation; US & Europe; across all stages	Series B
DeNovo Ventures	Saratoga, CA, U.S.	medical device, biotechnology & healthdiagnostics; late stage	Series C
Aperture Venture Partners	New York, U.S.	medical device, pharmaceutical, healthcare IT/services, diagnostic medical tech, Saas, home consumer	Series C
Crescent Enterprises Venture Capital	Sharjah, Sharjah, United Arab Emirates	emerging tech; globally; across all stages	Series C
Action Potential Venture Capital	Cambridge, Massachuettts, U.S	bioelectronic medicine and technology across all stages	Series C
LifeSci Venture Partner	New York, U.S.	molecular medicine, medtech, healthcare delivery; mid-late stage	Series C

Appendix III: CKD treatment roadmap



(AstraZeneca 2020)

Appendix IV - Memo: Correspondence with Cre8tek

Continuous correspondence via email with Niels Harry Olesen, Business Developer and Customer Care (Partner) at Cre8tek Denmark ApS. Between 20 April to 2 May 2022.

Key takeaways:

- The typical product journey of bringing a product from concept to final delivery from China involves 12 steps: 1) Kick-off meeting, 2) Conceptual design, 3) Detailed development, 4) Prototype production, 5) Testing and verification, 6) Manufacturing of tools, 7) Manufacturing of mechanical components, 8) Supply Chain Management, 9) Assembly Manufacturing, 10) Quality control, 11) Packaging and shipping, and 12) Arrival at the customer.
- The proposed product journey incurs costs of between DKK 100.000 and DKK 1.000.000 depending on the need for bespoke parts and the manufacturer's willingness to do customization.

Appendix V - Memo: Interview with Andy D.

Continuous correspondence via email with Andy D., Business Development Manager at Virtue Legal Services. 17 May 2022.

Key takeaways:

- Using the Patent Cooperation Treatment, it is easier to file for patents in multiple countries for up to 30 months after the first filing.
- Ahead of the filing of a patent, it is normal to 1) Do a patentability search, 2) investigate the freedom to operate, and 3) potentially investigate the state of the art within the field one is seeking a patent. All these studies will provide insights into the existing patent market, and can be used to look for opportunities.
- A patentability search aims to uncover whether the product can be patented in the first place. It costs around 500\$ and is applicable worldwide. A “Freedom to Operate” study costs around 2000\$ per country and seeks to mitigate the risk of infringement of an existing patent.
- The filing for a provisional patent in one country, e.g., the U.S., can cost upwards of 15.000\$ if performed by one of the big law firms. A provisional patent lasts 12 months whereafter you must file for a non-provisional/utility patent incurring similar costs.

Appendix VI - Memo: Correspondence with Paulo Zoio

Continuous correspondence via email with Paulo Zoio, the initial inventor and case provider.

4 April to 17 May 2022.

Key takeaways:

- Sweat was used for the proof of concept but faced complaints from volunteers due to the need to induce the sweat response using drugs. Hence ISF was chosen as the alternative.
- Currently, the device is in an early prototype stage using OEM parts and with a significant need ahead of it to make it smaller. It is therefore necessary to create further concepts and design for the hardware itself.
- The device mainly consists of microelectronics, chips, and optical elements for the sensor.
- Previous studies on sweat for prediction gave an AUC of 0.750 for diagnostics, and these are sought to be repeated using ISF and for prognosis as well. The software does signify a crucial element of the product.


Appendix VII - Memo: Correspondence with Tony Orsi

Continuous correspondence via email with Tony Orsi, Partner, Bereskin & Parr LLP. 5 May to 18 May 2022.

Key takeaways:

- Patents are awarded based on 5 criteria: 1) Has to be in a patentable area, 2) Must include new features, 3) The features have to be inventive or non-obvious, 4) The invention must provide utility, and 5) It must be described with enough detail to be recreated.
- For our device, there might be opportunities to patent the sensor, circuitry, and the way our AI is used alongside how it is fed and preprocesses the data. In general, companies use a mixture of trademarks, design patents, utility patents, trade secrets, and copyright to protect their inventions and achieve different corporate goals.
- Normally one does a patent search to see what the existing state of the art is and determine whether the product is patentable in the first place. It also provides insights into the area one seeks to obtain one or more patents alongside potential competitors and collaborators.
- The cost of filing a patent in the U.S. will be between \$7 - \$15k CDN with \$1k CDN in fees. A patent application in the EU is between \$8 – \$12k CDN. The cost of filing a PCT application is between \$6 to \$15k.
- After a patent is filed, it can take between 1 - 3 years for the first report from the examiner to arrive. The response to this report costs around \$1.5 – \$5k. The entire process to get a patent takes between 2 – 5 years.
- In general, the process goes 1) File for the provisional U.S. patent, 2) After 12 months elevate it to a PCT application, and 3) File for national patents after 18 months.

Appendix VIII: Timeline & key milestones



Group Contribution

Appendix IX: Income statement forecast

In American USD \$	ESTIMATION PERIOD											
	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	
Demand								8.510.000,00	28.720.000,00	68.845.000,00	88.645.000,00	
Revenue								\$16.169.000.000,00	\$64.780.000.000,00	\$175.481.500.000,00	\$295.715.500.000,00	
growth in %									301%	171%	69%	
COGS								\$936.100.000,00	\$3.159.200.000,00	\$7.572.950.000,00	\$9.750.950.000,00	
Gross Profit								\$15.232.900.000,00	\$61.620.800.000,00	\$167.908.550.000,00	\$285.964.550.000,00	
Total Operating expenses	\$1.371.510,00	\$2.989.000,00	\$3.385.000,00	\$4.896.000,00	\$3.385.000,00	\$2.147.000,00	\$3.189.000,00	\$2.735.000,00	\$3.005.000,00	\$2.999.000,00	\$3.579.000,00	
% sales												
research & development	\$467.000,00	\$1.960.000,00	\$2.629.000,00	\$2.629.000,00	\$2.629.000,00	\$1.379.000,00	\$1.379.000,00	\$1.379.000,00	\$1.379.000,00	\$1.379.000,00	\$1.379.000,00	
general & administrative	\$904.510,00	\$1.029.000,00	\$756.000,00	\$2.267.000,00	\$756.000,00	\$768.000,00	\$1.330.000,00	\$834.000,00	\$954.000,00	\$948.000,00	\$1.648.000,00	
sales & marketing							\$480.000,00	\$522.000,00	\$672.000,00	\$672.000,00	\$552.000,00	
EBIT	-\$1.371.510,00	-\$2.989.000,00	-\$3.385.000,00	-\$4.896.000,00	-\$3.385.000,00	-\$2.147.000,00	-\$3.189.000,00	\$15.230.165.000,00	\$61.617.795.000,00	\$167.905.551.000,00	\$285.960.971.000,00	
EBIT margin								94,19%	95,12%	95,68%	96,70%	
EBITDA	-\$1.371.510,00	-\$2.989.000,00	-\$3.385.000,00	-\$4.896.000,00	-\$3.385.000,00	-\$2.147.000,00	-\$3.189.000,00	\$15.230.165.000,00	\$61.617.795.000,00	\$167.905.551.000,00	\$285.960.971.000,00	
EBITDA margin								94,19%	95,12%	95,68%	96,70%	
Operating Cash Flow												
Cash inflow								\$16.169.000.000,00	\$64.780.000.000,00	\$175.481.500.000,00	\$295.715.500.000,00	
Cash outflow	\$1.371.510,00	\$2.989.000,00	\$3.385.000,00	\$4.896.000,00	\$3.385.000,00	\$2.147.000,00	\$3.189.000,00	\$938.835.000,00	\$3.162.205.000,00	\$7.575.949.000,00	\$9.754.529.000,00	
Total operating cashflow	-\$1.371.510,00	-\$2.989.000,00	-\$3.385.000,00	-\$4.896.000,00	-\$3.385.000,00	-\$2.147.000,00	-\$3.189.000,00	\$15.230.165.000,00	\$61.617.795.000,00	\$167.905.551.000,00	\$285.960.971.000,00	

Appendix X: Estimated patent costs

Assumptions:

U.S. filing costs assumed for Japan and China.
All maintenance costs being the same as the U.S.
Highest prices given are the ones that will be incurred.

Total countries	4
Total patents	25

Sources:

<https://patenttranslationexpress.com/patent-translation-services/>
Response from Bereskin & Parr
Response from Virtue Legal Services

In American USD \$	ESTIMATION PERIOD											
	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	
Patentability Search	\$4.000,00											
Freedom to Operate report	\$8.000,00											
Filing of U.S. patent	\$175.000,00	\$375.000,00		\$375.000,00			\$125.000,00					
Filing of EU patent				\$300.000,00			\$125.000,00					
Filing of JP patent				\$425.000,00			\$125.000,00					
Filing of CN patent				\$411.000,00			\$125.000,00					
Maintenance fees (due 3 & 7 years after IP filing)							\$2.000,00				\$700.000,00	
File a U.S. utility patent	\$15.000,00											
File a U.S. provisional patent	\$7.000,00											
File EU patent	\$12.000,00											
Patent searching	\$4.000,00											
Respond to examiner's report	\$5.000,00											
PCT application incl. fees	\$15.000,00											
English to Japanese	\$2.070,00											
English to Chinese	\$1.440,00											
Freedom to Operate	\$2.000,00											
TOTAL	\$250.510,00	\$375.000,00	\$0,00	\$1.511.000,00	\$0,00	\$0,00	\$502.000,00	\$0,00	\$0,00	\$0,00	\$700.000,00	

Group Contribution

Appendix XI: interview overview with different stakeholders

Number	Category	Name	Expertise/Position	Company/Institute
1	direction of the company	Paulo		
2	patient	N/A		
3	patient	N/A		
4	patient	N/A		
5	patient	N/A		
6	pharmacy	Schekeb Haschemi	Process Specialist, pharmacist	GSK; Post-Apotheke
7	Nephrologist	Miguel Bigotto Vieira	Nephrologist; Member of the American Society of Nephrology	Centro Hospitalar Universitario de Lisboa Central
8	Scientific evaluation	Can Diner	Joniur research group leader for Disposable Microsystems; Biosensors & Bioelectronics Best Paper Award;	University of Freiburg
9	Scientific evaluation/direction of the company	Filipe Quinaz	CEO, masters degree in computer engineering and pursuing a Ph.D in Biomedicine	Nuada, Criam
10	Manufacturing	Niels Harry Oelsen	Business Development & Customer Care (Partner)	Cre8tek Denmark Aps
11	Manufacturing	Alice Lee	Sales Manager	iSmarch
14	exit options	João Santos Pereira	CEO who did a successful healthtech M&A in 2020	
15	IP strategy	Andy D	Business Development Manager	Virtue Legal Services
16	Laywer/IP strategy	Tony Orsi	Managing Partner; Lead of Medical Device Group;	Cooley LLP
17	Laywer/IP strategy	Sabrina Morales	Head of Executive Committee	Cooley LLP
18	funding strategy	Andreas Wüpper	Investment Director	Fresenius Medical Care Ventures